

11. Světlík S, Hronová K, Slanář O. Fenotypizace enzymů podléhajících se na metabolismu léčiv. *Čes slov Farm.* 2012;61(3):115-26.
12. Bousman ChA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. *Clinical Pharmacology and Therapeutics.* 2023;114(1):51-68.
13. Porcelli S, Fabbri Ch, Serretti A. Meta-Analysis of Serotonin Transporter Gene Promoter Polymorphism (5-HTTLPR) Association with Antidepressant Efficacy. *European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology.* 2012;22(4):239-258.
14. Hahn M, Müller DJ, Roll SC. Frequencies of Genetic Polymorphisms of Clinically Relevant Gene-Drug Pairs in a German Psychiatric Inpatient Population. *Pharmacopsychiatry.* 2021;54(2):81-89.
15. Sládková Kavinová H, Dorofeev A. Farmakogenetické vyšetření v psychiatrické praxi v ČR. *Acta Medicinæ.* 2023;16:36-39.
16. Tašková I. Terapeutické monitorování psychofarmak z pohledu klinického farmaceuta: doporučení versus praxe. *Remedia.* 2020;30:650-656.
17. Scherf-Clavel M, Frantz A, Eckert A, et al. Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study. *Int J Clin Pharm.* 2023;45(5):1107-1117.
18. European Medicines Agency. Guideline on the investigation of drug interactions [online]. 2012 [cit. 17. 4. 2025]. Dostupné z: <https://www.ema.europa.eu/>.
19. The Flockhart Cytochrome P450 Drug-Drug Interaction Table. Updated 2021. [online]. Dostupné z: <https://drug-interactions.medicine.iu.edu/>
20. Center for Drug Evaluation, and Research. 2025. "For Healthcare Professionals." U.S. Food and Drug Administration. FDA. [online]. June 27, 2025. Dostupné z: <https://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems>.
21. University of Florida Health. CYP2D6 phenoconversion calculator [online]. Přístup 31. 3. 2025. Dostupné z: <https://precisionmedicine.ufhealth.org/>.
22. Cicali EJ, Elchynski AL, Cook KJ, et al. How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial. *Clin Pharmacol Ther.* 2021;110(3):677-687.
23. Bloch MH, McGuire J, Landeros-Weisenberger A, et al. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. *Mol Psychiatry.* 2010;15(8):850-855.
24. Schulz M, Schmoltdt A, Andresen-Streichert H, et al. Revisited: Therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics. *Crit Care.* 2020;24:195.
25. Chen R, Shen K, Hu P. Single- and multiple-dose pharmacokinetics and tolerability of a paroxetine controlled-release tablet in healthy Chinese subjects. *Int J Clin Pharmacol Ther.* 2017;55(3):231-236.
26. DrugBank Online. Paroxetin [online]. Edmonton (AB): DrugBank; 2024 [cit. 19. 4. 2025]. Dostupné z: <https://go.drugbank.com/drugs/DB00715>.
27. Remood 20 mg tablety. Souhrn údajů o přípravku (SPC) [online]. Praha: Medicom International; [cit. 19. 4. 2025]. Dostupné z: <https://www.sukl.cz/>.
28. Paroxetine: Drug information [online]. UpToDate. Waltham (MA): UpToDate, Inc.; 2024 [cit. 19. 4. 2025]. Dostupné z: <https://www.uptodate.com/>.
29. Hilleret H, Voiron P, Bovier P, et al. Very long half-life of paroxetine following intoxication in an extensive cytochrome P4502D6 metabolizer. *Ther Drug Monit.* 2002;24(4):567-569.
30. Bertelsen KM, Venkatakrishnan K, Von Moltke LL, et al. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. *Drug Metab Dispos.* 2003;31(3):289-293.
31. Saito M, Yasui-Furukori N, Nakagami T, et al. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. *J Clin Psychopharmacol.* 2005;25(6):527-532.
32. Hahn M, Roll SC. The role of phenoconversion in the pharmacogenetics of psychiatric medication. *Pharmacogenomics.* 2023;24(9):485-487.